Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
zoledronic acid
Novartis Pharmaceuticals
Paget's Disease of Bone
1 trial -
AUY922
Novartis Pharmaceuticals
Advanced HER2-positive Breast Cancer
1 trial -
Asciminib, ASCIMINIB HYDROCHLORIDE
Novartis Pharmaceuticals
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
1 trial -
BGG492
Novartis Pharmaceuticals
Adrenocortical Adenoma
1 trial -
BGJ398
Novartis Pharmaceuticals
Recurrent Glioblastoma or Other Glioma Subtypes
1 trial -
BION-1301 Single Dose
Novartis Pharmaceuticals
IgA Nephropathy
1 trial -
Bion 1301/FUB523
Novartis Pharmaceuticals
IgA nephropathy
1 trial -
CAAA601A42101
Novartis Pharmaceuticals
Extensive stage small cell lung cancer (ES-SCLC)
1 trial -
CAAA603D12101
Novartis Pharmaceuticals
Breast Cancer
1 trial -
CAAA614A12101
Novartis Pharmaceuticals
Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)
1 trial -
CAAA617A12202
Novartis Pharmaceuticals
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.
1 trial -
CAAA617B12203
Novartis Pharmaceuticals
PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
1 trial -
CAAA617H12101
Novartis Pharmaceuticals
Metastatic neuroendocrine prostate cancer
1 trial -
CAAA802A12101
Novartis Pharmaceuticals
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
1 trial -
CABL001E2201
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
1 trial -
CABL001I12201
Novartis Pharmaceuticals
Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors
1 trial -
CABL001L12101
Novartis Pharmaceuticals
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
1 trial -
CADPT09A12201
Novartis Pharmaceuticals
Idiopathic pulmonary fibrosis
1 trial -
CADPT15A12201
Novartis Pharmaceuticals
Atherosclerotic cardiovascular disease
1 trial -
CADPT17A12201
Novartis Pharmaceuticals
Moderate to severe atopic dermatitis
1 trial -
CAMN107AIT15
Novartis Pharmaceuticals
Chronic myeloid leukemia
1 trial -
CAMO959A12103
Novartis Pharmaceuticals
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
1 trial -
CBYL719F12201
Novartis Pharmaceuticals
PIK3CA-Related Overgrowth Spectrum (PROS)
1 trial -
CBYL719F12202
Novartis Pharmaceuticals
PIK3CA-Related Overgrowth Spectrum (PROS)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.